ALNYLAM PHARMACEUTICALS, INC. ALNY Balance Sheet

Alnylam pharmaceuticals, inc. (ALNY)

Balance Sheet / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Dec'09
ASSETS
Current assets:
Cash and cash equivalents
467	547	923	1,136	724	420	316	361	396	645	202	408	171	193	168	271	231	180	149	151	306	75	82	80	350	53	11	24	97	51	75	48	61	70	74	67	90	74	46	66	137
Marketable debt securities
836	975	797	790	519	662	905	1,074	1,171	1,045	746	514	385	424	531	571	748	848	828	788	660	526	507	524	314	192	181	184	138	71	152	180	137	76	98	150	154	158	184	193	143
Marketable equity securities
38	13	-	-	-	1	15	12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable, net
75	43	48	30	33	18	3	2	50	34	14	15	19	23	15	9	8	8	8	9	10	39	0	0	0	4	0	0	0	0	1	4	2	1	2	1	1	3	4	6	6
Inventory
68	56	54	40	32	24	11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment in equity securities of Regulus Therapeutics Inc.
-	-	-	-	-	-	-	-	-	-	-	-	2	8	13	13	33	51	38	64	99	94	41	49	55	45	57	60	47	38	-	0	0	-	1	1	2	3	0	1	6
Income taxes receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	10	-	-	0
Prepaid expenses and other current assets
98	80	73	65	81	73	90	51	66	40	30	22	18	21	19	22	27	16	17	15	13	9	10	10	8	3	4	4	3	2	5	6	7	4	4	5	4	6	6	6	4
Deferred tax assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	1
Total current assets
1,584	1,715	1,897	2,063	1,392	1,200	1,342	1,502	1,685	1,764	993	960	597	671	747	888	1,050	1,105	1,041	1,029	1,090	746	643	665	674	254	199	214	240	125	235	240	208	152	179	224	250	254	244	273	293
Marketable debt securities
-	-	-	-	-	-	-	-	0	13	51	174	255	324	339	287	228	251	358	456	483	279	324	350	335	104	173	169	164	103	67	63	117	114	113	98	98	116	140	137	153
Deferred tax assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	19	33	31	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8	8	8
Property, plant and equipment, net
429	425	396	371	341	320	272	227	201	181	161	147	129	114	74	55	36	27	26	25	21	21	18	16	15	16	16	18	18	19	18	14	13	14	15	16	17	18	18	18	18
Operating lease right-of-use assets
221	221	223	226	226	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted investments
24	14	14	44	44	44	44	44	30	30	150	150	150	150	150	150	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other assets
19	18	9	9	9	8	16	14	5	4	1	1	1	1	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-
Intangible assets, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0
Total assets
2,279	2,395	2,541	2,716	2,013	1,574	1,675	1,789	1,923	1,994	1,358	1,434	1,133	1,262	1,312	1,382	1,316	1,386	1,436	1,530	1,628	1,079	986	1,032	1,080	420	447	462	471	287	322	318	340	281	310	340	369	393	412	440	481
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
40	49	39	71	22	59	21	11	13	28	9	23	25	54	23	12	17	16	14	15	15	15	5	6	5	5	2	4	3	4	5	5	4	5	5	7	5	9	6	10	12
Accrued expenses
183	197	177	138	106	112	93	89	63	72	51	43	31	42	36	37	30	28	18	17	14	23	19	15	16	14	15	8	9	11	14	14	13	12	12	11	12	11	10	7	9
Operating lease liability
29	27	28	29	16	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9	19	33	31	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liability for stock issuance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued intraperiod tax allocation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	-	0	4	6	-	2	5	3	-	-	-	-	-	-	-	-	-	-	-	-
Income taxes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	5
Deferred rent
-	-	0	-	-	3	2	2	2	1	2	1	1	1	1	1	1	1	1	1	1	1	0	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
Deferred revenue
86	77	107	89	2	3	3	9	35	41	38	39	36	33	21	18	16	15	13	12	14	23	30	27	29	32	33	33	33	31	31	35	48	62	75	80	81	81	81	83	81
Investment in joint venture (Regulus Therapeutics Inc.)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2	-1	-0	-	-	-	-	-	-	-	-
Total current liabilities
338	352	352	328	149	179	121	113	115	144	101	108	95	131	81	70	66	62	57	66	80	95	56	53	83	53	54	53	49	48	54	57	66	80	93	100	99	102	99	102	110
Operating lease liability, net of current portion
275	276	276	277	282	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent, net of current portion
-	-	0	-	-	57	40	16	10	6	7	7	8	8	8	6	6	5	5	5	5	5	4	3	2	2	3	3	4	4	4	4	3	3	2	2	2	2	2	2	2
Deferred revenue, net of current portion
306	318	296	313	0	0	1	4	7	43	38	42	46	49	55	54	53	52	52	50	46	42	20	32	37	93	91	97	105	100	85	68	72	78	84	100	120	129	149	169	189
Long-term debt
-	-	0	30	30	30	30	30	30	30	150	150	150	150	150	150	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
9	9	9	9	5	4	4	4	4	4	2	2	3	3	1	1	1	1	-	-	-	-	0	1	1	-	-	-	-	-	0	0	0	0	0	0	1	0	-	0	0
Total liabilities
929	956	934	959	467	272	197	168	168	228	299	311	303	342	297	283	127	121	114	122	132	143	81	90	125	150	149	154	160	153	145	130	142	163	182	204	223	235	251	274	303
Commitments and contingencies (Note 14)
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	0	-	-	-
Stockholders’ equity:
Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of March 31, 2020 and December 31, 2019
0	0	0	-	-	0	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Common stock, $0.01 par value per share, 250,000 shares authorized; 113,168 shares issued and outstanding as of March 31, 2020; 112,188 shares issued and outstanding as of December 31, 2019
1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Additional paid-in capital
5,289	5,201	5,091	5,034	4,601	4,175	4,140	4,037	4,009	3,947	3,097	3,038	2,627	2,609	2,585	2,565	2,546	2,506	2,483	2,468	2,450	1,843	1,823	1,810	1,776	846	833	813	806	624	621	613	609	518	514	509	504	500	495	490	476
Accumulated other comprehensive loss
-32	-36	-34	-35	-32	-33	-33	-33	-34	-34	-33	-33	-33	-33	-27	-28	-9	4	-7	18	52	48	15	21	25	19	27	28	20	15	0	-0	-0	-0	-0	-0	-0	0	1	1	0
Accumulated deficit
-3,909	-3,727	-3,450	-3,242	-3,022	-2,840	-2,629	-2,384	-2,220	-2,147	-2,005	-1,882	-1,764	-1,656	-1,543	-1,439	-1,349	-1,246	-1,155	-1,079	-1,007	-956	-935	-891	-847	-596	-563	-534	-516	-507	-444	-425	-412	-400	-386	-373	-359	-343	-336	-326	-299
Total stockholders’ equity
1,349	1,438	1,607	1,757	1,546	1,301	1,478	1,620	1,754	1,766	1,058	1,122	830	920	1,014	1,098	1,189	1,264	1,321	1,408	1,496	936	904	942	954	270	297	308	311	134	177	188	197	117	127	136	145	158	160	165	177
Total liabilities and stockholders’ equity
2,279	2,395	2,541	2,716	2,013	1,574	1,675	1,789	1,923	1,994	1,358	1,434	1,133	1,262	1,312	1,382	1,316	1,386	1,436	1,530	1,628	1,079	986	1,032	1,080	420	447	462	471	287	322	318	340	281	310	340	369	393	412	440	481
Preferred stock, par value (in dollars per share)
0.01	0.01	0.01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred stock, shares authorized (in shares)
5	5	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred stock, shares issued (in shares)
0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred stock, shares outstanding (in shares)
0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock, shares outstanding (in shares)
113	112	111	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	0	-	-	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent, net of current portion
-	-	0	-	-	57	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-